isabelobrien, Author at European Medical Journal - Page 12 of 65

Gold crown on blue background

AstraZeneca ranks top in science graduates' survey

Rising one place to number one overall, the British drugmaker has overtaken the NHS as the preferred destination for these graduates.

Handshake on green background

Bayer’s Stefan Oelrich elected as new EFPIA President

Stefan Oelrich has been newly elected President of the EFPIA, as new leadership calls for action to restore Europe’s global leadership in pharma innovation.

Analysing key trends in medical affairs in 2025

Dive into the latest insights from EMJ GOLD’s contributors to uncover what HCPs really want from medical affairs in 2025.

Hurdles on blue backgound

FDA removes hurdle to CAR T-cell therapies

The body is eliminating of Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed CAR T-cell therapies.

Purple briefcase on grey background

Sun Pharma appoints Richard Ascroft as North American CEO

Ascroft brings more than 30 years of industry experience, including senior roles at Takeda Pharmaceuticals.

Torn agreement

US withdraws funding from Gavi, the Vaccine Alliance

The US plans to stop its financial contributions to Gavi, the Vaccine Alliance, marking an end to an over 20-year partnership.

Lennard Lee

Onc Now: Episode 20: How Cancer Vaccines Are Changing Medicine

Lennard Lee, Associate Professor of Cancer Vaccines at the University of Oxford, shares how large-scale collaboration is shaping the future of cancer vaccines and oncology innovation.

Philips’ Dr Carla Goulart Peron on AI, equity and the future of care

How can AI expand healthcare access without losing the human touch? Philips’ CMO Dr Carla Goulart Peron shares all.

Illustration of a doctor talking to a patient at a desk

New survey takes patient pulse on AI in healthcare

The survey found that, while 57% of patients support the use of AI in the examination room, they are less enthusiastic about diagnostics.

Pfizer’s Richard Maughan on the future of access in the UK

Richard Maughan, Senior Director and Head of UK Policy and Public Affairs, Pfizer, explores how the UK is shaping access to medicine.